Biopharmaceutical manufacturer Hospira has found itself in something of a hairy situation—literally. In a 30 August 2013 announcement, the company said it was voluntarily initiating a voluntary recall of one lot of Aminosyn, an amino acid solution administered intravenously, after a customer reported finding an "unknown foreign particle" in the injection port of the product. That "foreign particle," Hospira explained, was human hair—a decidedly non-sterile organic addition to an injectable product that requires high levels of sterility.